Hints and tips:
Related Special Reports
...His line on it was: we were playing with a ChatGPT equivalent two years ago within Google and — for whatever reason — there was just this hesitation about putting it into consumers’ hands....
...Genetic testing company 23andMe has grand ambitions for personalised healthcare....
...The private arm of Ariel Investments, one of the largest black-owned asset managers in the US, has bought a majority stake in a video communications provider for deaf consumers for $1.3bn, in the first of...
...Peltz had built a stake in the early months of 2022, after Unilever’s share price slumped following its botched attempt to buy GlaxoSmithKline’s consumer healthcare arm, later spun out as Haleon....
...This nascent healthcare group would quickly establish itself as go-to advisers to various big pharma clients including Pfizer....
...Haleon, GlaxoSmithKline’s consumer healthcare venture with Pfizer, is down about 5 per cent from its July listing price....
...Risky risk on Here’s an updated version of one of our go-to charts, sector performance within the S&P 500: The most defensive sectors — utilities, healthcare, consumer staples — are the bottom of the league...
...The impact of the digital economy extends beyond the consumer sector....
...Paul Pharoah, professor of cancer epidemiology at Cedars-Sinai, a non-profit healthcare organisation in Los Angeles, said early detection tests had been “overhyped”, as there was still no proof they could...
...The team offers a global perspective on telehealth, which is the use of technology to access healthcare and related digital health products....
...GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a £50bn takeover offer from Unilever...
...In 2019, he raised “serious doubts” about the finances of healthcare operator NMC Health, which later collapsed amid allegations of fraud....
...GlaxoSmithKline: shingle minded Worried about shingles? GlaxoSmithKline is....
...The consumer health spin-off will give GSK more money to spend on deals and invest in research and development....
...Job moves Alan Jope is to retire as chief executive of Unilever at the end of 2023 following investor discontent over lacklustre performance during his time leading one of the world’s largest consumer goods...
...Its failed attempts to buy UK drugmaker GlaxoSmithKline’s consumer healthcare business, a politically fraught fight with Ben & Jerry’s and the arrival of the billionaire activist Nelson Peltz on Unilever...
...GlaxoSmithKline chief executive Emma Walmsley said the imminent spin-off of the consumer health division Haleon would untangle the UK drugmaker’s complex “Gordian knot” structure and enable her to tackle...
...Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18....
...The US parent of Boots put the business up for sale last December to focus on healthcare in its domestic market....
...Emma Walmsley, the drugmaker’s chief executive, said it had delivered “strong first-quarter results in this landmark year for GSK”, as it prepared to spin off its consumer healthcare division into a company...
...Here are numbers 8, 9, 11, 12 and 14, which will also enjoy all the advantages of being absolutely immense companies: Here are a diversified healthcare company (in pharma, medical equipment, and consumer...
...Reliance has recently invested in healthcare companies including genetics group Strand Life Sciences, after buying a majority stake in pharma sales company Netmeds in 2020....
...Unilever has said it will not increase its offer for GSK Consumer Healthcare above £50bn, drawing a line under its pursuit of the division owned by GlaxoSmithKline and Pfizer after a backlash from investors...
...Unilever has defended its plan to acquire the consumer health division of GlaxoSmithKline following scepticism from analysts about its £50bn bid....
...GlaxoSmithKline expects to spin off its consumer healthcare joint venture Haleon in July, as the UK drugmaker presses on with plans for the largest demerger in Europe in the past 20 years....
International Edition